Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Results 1-25 of 378 for your search:
Start Over
Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System
Status: Active
Phase: Phase IV
Type: Treatment
Age: 40 and over
Trial IDs: CTPR-0009, NCI-2013-01601, NCT01644669
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Standard of Care Therapy with or without Stereotactic Radiosurgery and/or Surgery in Treating Patients with Limited Metastatic Breast Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR002, NCI-2014-01810, NCT02364557
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2303, NCI-2013-00017, 2012-002571-34, NCT01633060
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP-B-51, NCI-2012-03198, NSABP-B-51/RTOG-1304, NSABP PROTOCOL B-51/RTOG PROTOCOL 1304, NCT01872975
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011202, NCI-2013-00875, NCT01901094
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PR-30-5010-C, NCI-2014-00678, 1307-BCG, 1307-BCG, BIG5-13, NCT01905592
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, B-55/BIG 6-13, BIG 6-13, D081CC00006, NSABP B-55/BIG 6-13, NCT02032823
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7389-A001-303, NCI-2014-01285, NCI-2014-00255, RU011201I, NCT02037529
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70, Postmenopausal
Trial IDs: A5481027, NCI-2015-01375, JS14185, NCT02297438
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over, postmenopausal
Trial IDs: CLEE011F2301, NCI-2015-01088, NCT02422615
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Platinum Based Chemotherapy or Observation in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Start Over